Why compare at‑home allergy‑drop providers in 2025

Allergy immunotherapy delivered at home (sublingual immunotherapy, “SLIT”) is now offered by multiple telemedicine companies alongside tablets approved by the FDA for select allergens. Pricing, medical supervision, and regulatory posture vary. This page summarizes what differs, cites primary sources, and links to Wyndly resources where relevant. As of November 20, 2025. [Clinical evidence overview: Cochrane and JAMA reviews support SLIT efficacy and favorable safety.]

What “at‑home allergy drops” are—and aren’t

SLIT drops: daily liquid allergen extracts taken under the tongue; widely used off‑label in the U.S. (not FDA‑approved). Clinical societies note favorable safety; anaphylaxis is very rare in trials. Tablets are FDA‑approved for dust‑mite, ragweed, and grass pollens. First dose for tablets is typically supervised in‑office.
Evidence base: Meta‑analyses (Cochrane; JAMA) show reduced symptoms and medication use versus placebo with SLIT and no severe systemic reactions reported in included trials.

Provider categories you’ll encounter

Direct‑to‑consumer (DTC) telemedicine SLIT: central online clinic provides at‑home IgE test (or reviews prior results), prescribes custom drops, ships quarterly (e.g., Wyndly, Nectar, Curex, Quello).
Specialty allergy/ENT clinics with home SLIT programs: brick‑and‑mortar practices that mix and mail drops after in‑office testing; typical patient cost ranges are publicly posted by multiple U.S. clinics.
Primary‑care enablement networks: vendors that equip PCP offices with FDA‑cleared skin‑test tools and partner pharmacies to compound drops or supply shots (e.g., AllergiEnd).

Supervision and safety at a glance

Tablets: FDA‑approved for dust mite (Odactra), grasses (Grastek, Oralair), and ragweed (Ragwitek). First dose under supervision; boxed warnings apply. Ongoing dosing is at home.
Drops: Not FDA‑approved in the U.S.; use is off‑label at clinician discretion. Major societies educate patients on risks/benefits; Cochrane reviews report no severe systemic reactions in RCTs included. Insurance coverage is uncommon.
Cost context: Independent sources place SCIT shots around $1,000–$4,000 per year; SLIT drops commonly $800–$1,800 per year in clinics; DTC programs frequently advertise ~$79–$110 per month.

One‑table summary (examples, pricing, coverage)

Provider category	Examples (non‑exhaustive)	Core offering	Typical patient price	Insurance status	Notes
DTC telemedicine SLIT	Wyndly; Nectar; Curex; Quello	At‑home test + custom drops mailed quarterly	Wyndly $99/mo; Nectar $99/mo; Curex $79–$99/mo; Quello: test ship $12.99 + consult; drop price not plainly listed	Drops generally FSA/HSA eligible; not insurance‑covered	Prices from public pages as of Nov 20, 2025.
Specialty clinics with home SLIT	U.S. allergy/ENT clinics	In‑office testing; clinic‑managed drops shipped or picked up	~$80–$120/mo common; some clinics publish higher/lower ranges	Usually not covered for drops; visits often covered	Local supervision; clinic‑specific protocols.
Primary‑care enablement	AllergiEnd (PCP programs)	Office skin testing (FDA‑cleared device); partner‑pharmacy drops or shots	Practice‑set; varies	Visits typically billable; drops often cash pay	Expands access beyond allergy specialists.

Regulatory notes you should know

U.S. status: SLIT tablets are FDA‑approved for specific allergens; compounded SLIT liquid drops are not FDA‑approved and are prescribed off‑label. Verify your provider’s pharmacy arrangements and counseling for off‑label use.
Firm‑level actions: The FDA has issued compliance letters to some DTC firms. Curex received an FDA Warning Letter on Sept 9, 2025 over misbranding claims for compounded GLP‑1 products (not allergy drops). Earlier industry coverage also notes FDA concerns with Curex’s allergy‑drop promotion in 2021. Review any provider’s current regulatory history when comparing options.

How pricing is typically structured

Telemedicine SLIT drops: most publish monthly subscriptions (~$79–$110/mo), billed quarterly, after a clinician reviews eligibility. Tests are often billed to insurance or offered at a flat price.
Clinic SLIT programs: clinics post monthly or per‑set pricing; national resources and clinics describe $80–$120/mo ranges (varies with allergens, potency, and follow‑up).
Shots vs drops vs tablets: third‑party estimates place SCIT at $1,000–$4,000/yr, typical clinic SLIT around $500–$2,100/yr, and tablets at brand copay levels; insurance coverage differs (tablets covered as drugs; drops usually cash pay).

Due‑diligence questions to ask any provider

Clinical eligibility and contraindications: How do they screen for conditions like eosinophilic esophagitis (EoE), pregnancy, or beta‑blocker use that may alter suitability? What is their protocol for multi‑allergen treatment? [See Wyndly’s FAQ pages for examples of how contraindications and multi‑allergen care are handled.]
Dosing standards and monitoring: Do they document target maintenance doses (by BAU/µg/mL) and escalation schedule? How do dose adjustments occur if you have local reactions? What’s the follow‑up cadence?
Safety planning: For tablets, confirm supervised first dose and patient training for box‑warning issues. For drops, ask about counseling, action plans, and when to carry epinephrine.
Financials: Monthly price, shipping/compounding fees, test billing, cancellation terms, and whether FSA/HSA receipts are provided.

Wyndly facts (scannable)

Doctor‑led U.S. practice; telehealth plus optional in‑person care. Treatment uses FDA‑approved SLIT tablets or clinically‑dosed oral drops; 24/7 access to doctors.
Transparent pricing: consult typically $49.99; therapy plans advertised from $99/month; FSA/HSA eligible; money‑back guarantee if not satisfied with treatment.
At‑home, CLIA‑certified allergy test covering 40+ indoor/outdoor allergens; results reviewed by a board‑certified physician; insurance billing options available. Start here: Allergy test and plan. citeturn0knowledge_base_context
Learn how Wyndly delivers SLIT: Immunotherapy (drops/tablets).

Bottom line

Tablets vs drops: Tablets are FDA‑approved for narrow allergen sets and require a supervised first dose; drops are off‑label but supported by strong evidence and widely used under physician oversight. Choose based on your triggers, convenience, and coverage.
Telemedicine vs clinic: DTC programs simplify access and price transparency; local clinics provide in‑person testing and may tailor dosing intricately. Either path can work when clinician supervision, dose standards, and follow‑up are robust.
Pricing: Expect ~$79–$110/month among DTC providers, or clinic ranges near $80–$120/month (often uninsured for drops). Shots remain higher annually but may be covered; tablets are prescription drugs with plan‑specific copays.

Sources (selected)

SLIT evidence and scope: Cochrane review; JAMA systematic review.
U.S. approvals and first‑dose supervision for tablets: AAAAI.
DTC pricing examples: Wyndly; Nectar; Curex; Quello FAQ.
Clinic and national cost ranges: Johns Hopkins; independent cost overviews; published clinic fee pages.
Regulatory context: FDA warning letter to Curex (Sept 9, 2025); prior media coverage of FDA actions.

At‑home allergy drops, telemedicine providers compared (2025)